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Understanding Polarizing Community Perspectives on Harm Reduction 
Strategies: Challenges to Addressing the Opioid Crisis in Appalachian 
Pennsylvania 
Abstract 
Introduction: Rural communities face barriers to opioid treatment and overdose prevention including 
concerns about stigma and lack of harm reduction services. 
Purpose: The aim of this study was to explore community perspectives and understanding of harm 
reduction approaches to opioid use and overdose in a high-risk Northern Appalachian case community in 
Pennsylvania. 
Methods: A small town approximately 10 miles from Pittsburgh was identified as the community with the 
greatest predicted probabilities of epidemic outbreak using posteriors from spatial models of 
hospitalizations for opioid use disorders. We interviewed 20 key stakeholders in the case community in 
using a semi-structured interview guide and analyzed the qualitative data using an inductive grounded 
theory approach. 
Results: Our findings illustrate how conflicting perspectives about opioid dependence lay the foundation 
for the polarizing community perspectives on addressing opioid use and overdose and general 
disagreement regarding the legitimacy of harm reduction approaches versus abstinence-based recovery 
plans. Community members shared varying perspectives on multiple aspects of the opioid epidemic, 
including appropriate strategies, treatment, and overdose prevention methods and how community 
leaders and organizations should respond. 
Implications: Opinions, coupled with a general lack of education regarding opioid use and harm reduction 
options, make it challenging for small communities with limited resources to create comprehensive plans 
to address the opioid crisis. 
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INTRODUCTION 
 
onmedical prescription opioid use is concentrated in areas of the U.S. 
with large rural populations, including Appalachian PA.1–3 Similarly, the 
Appalachian region has substantially higher overdose mortality rates 
compared to the non-Appalachian U.S.4 To curtail the morbidity and mortality 
associated with problematic opioid use (opioid use disorder, or OUD) and 
overdose, a wide spectrum of OUD care and overdose prevention options exist, 
ranging from abstinence-based recovery to harm reduction strategies. Rural 
communities face barriers to opioid treatment from lack of treatment services, 
stigma and privacy concerns, increased economic deprivation, geographic 
barriers, and greater availability of opioids compared to urban areas.2,5 In 
addition to barriers created by systemic poverty in the region, distinctive 
characteristics of Appalachia affect the provision of treatment, including lack of 
access to health professionals or training in evidence-based treatment 
approaches.3–5  
 
Medications for opioid use disorder (MOUD), including methadone, 
buprenorphine, and naltrexone, is evidence-based treatment for people with 
OUD that can reduce cravings for opioids and withdrawal symptoms, among 
other benefits.6 MOUD is known to be effective at reducing opioid use disorder 
and overdose.7 This harm reduction strategy has been shown to improve patient 
survival, increase treatment retention, increase patients’ ability to sustain 
employment, and decrease illicit opiate use and other criminal activity.5,8,9 
However, MOUD is underutilized across the country, particularly in rural and 
non-urban areas and the Appalachian region4; for example, Kentucky, 
Tennessee, and West Virginia are three states that delayed use of MOUD and 
only recently began covering methadone treatment in their state Medicaid 
programs.4,10 The dearth of community providers who deliver MOUD causes 
barriers for individuals seeking this form of treatment.11 Additionally, lack of 
education about harm reduction strategies, the stigma of “substituting one drug 
for another,” and misunderstandings of side effects lead to underutilization of 
MOUD even when available.12–15  
 
In addition to MOUD, expansion of access to Naloxone was identified as a priority 
area for addressing the opioid crisis by HHS. Naloxone, an “opioid antagonist” 
used to quickly reverse the effects of opioid overdose, is one strategy to address 
opioid overdose prevention among a spectrum of harm reduction strategies, 
including syringe services programs (SSPs), fentanyl test strips, safe injection 
sites, housing first programs, and safer use education. Despite evidence of 
N 
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decreased opioid overdose deaths when Naloxone is available and administered, 
particularly in prehospital settings, the intervention remains underutilized 
outside metropolitan areas.12 Many areas are equipping emergency medical 
service (EMS) workers, police officers, professional organizations, and family 
members of individuals at risk for overdose.12 However, the effectiveness of 
efforts to improve Naloxone access, as well as perceptions of this expansion, in 
rural and non-urban areas is unknown.  
 
Structural barriers and the lack of education regarding the effectiveness of 
MOUD and harm reduction strategies like Naloxone may contribute to 
communities not allocating resources to these harm reduction approaches. 
Indeed, structural barriers to MOUD (e.g., transportation and time) are 
associated with disfavor for methadone treatment.16 Based on our findings, 
community beliefs around the success of abstinence-based recovery may reduce 
support for these harm reduction approaches. The view that MOUD and other 
harm reduction strategies do not render the individual “drug-free” conflicts with 
the treatment approaches of abstinence-based recovery programs, such as the 
12-step program and recovery houses that require sobriety and may be 
associated with beliefs that MOUD is not appropriate treatment.16  
 
While rural areas, particularly those in the Appalachian region, underutilize 
MOUD and Naloxone in their opioid treatment and overdose prevention efforts,4 
little information exists on use of these harm reduction approaches in non-urban 
areas near metropolitan centers (e.g., micropolitan areas or small towns in 
outlying or fringe counties from urban centers). It is unclear how social factors, 
such as community beliefs, influence the use and expansion of harm reduction 
modes of treatment and overdose prevention in communities where physical 
access may be less of a barrier than in rural areas but community characteristics 
(e.g., cultural practices or beliefs, socioeconomic factors, and access challenges) 
may greatly vary from urban settings. Furthermore, little is known about the role 
of community perspectives on implementation of these treatment options, such 
as mandated treatment and/or incarceration, or the role of police. Qualitative 
assessment of community beliefs is vital to informing interventions targeting 
opioid use in specific geographic locations. Therefore, the aim of this study is to 
explore community perspectives of MOUD and Naloxone, harm reduction 
approaches to opioid dependence and overdose, in a high-risk Northern 










Theoretical Framework  
The Social–Ecological Model was used to ground the work contextualizing the 
opioid crisis in Appalachian PA. The attributional theory of stigma, which 
posits the cause of a health problem is controllable or reversible by the 
individual, was used to focus the analysis. This perspective promotes a 
stigmatizing response to the individual who uses opioids.17 This is also 
evidenced by the language used by some researchers and treatment providers 
who describe “addiction” as a choice compared to a disease.17 Understanding 
participant responses through these theoretical perspectives connects the multi-
layered stigma around those who use opioids to the lack of policies, treatment 
options, and community support. 
 
Case Community Selection 
Zone Improvement Plan (ZIP) code–level spatial random effects model of 
hospitalizations for opioid use disorders was used (i.e., opioid abuse and/or 
dependence) in the state of PA from 2004 to 2014 (16,275 space–time units) to 
identify communities with the greatest predicted probabilities of epidemic 
outbreak.11,18 A discrete target area (i.e., case community) consisting of one 
Appalachian ZIP code with a population of 100+ was selected using results from 
those models in combination with the crude opioid use disorder (OUD) 
hospitalization rate for each ZIP code in 2014 according to ICD-9CM diagnoses 
from patient-level records of hospitalizations from the Pennsylvania Healthcare 
Cost Containment Council (PHC4).19 The case community, chosen among the 
identified communities due to its proximity to the study team, is located 
approximately 10 miles outside of Pittsburgh and has a population size around 
4500 people, is 1.62 miles, 94% white, with 15.8% of the population living below 
the poverty line and a household median income of $31,681.20 
 
Sample Recruitment 
Twenty key stakeholders in the case community were interviewed, including 
clinicians, treatment providers, and other interventionists (seven participants); 
residents who currently use or have a history of opioid use (eight participants); 
community leaders (e.g., mayoral staff, police—two participants); and family 
members of those with a history of opioid use (three participants). Stakeholders 
were identified through snowball sampling, with a goal of identifying drivers of 
the opioid epidemic, existing resources, and intervention opportunities within 
the community by speaking to a diverse range of individuals.  
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Data Collection 
A research assistant with qualitative data collection training and experience 
conducted in-depth interviews using a semi-structured field guide previously 
developed in a pilot study that informed this research by the PI of both studies 
and a research assistant with qualitative research experience. The field guide 
was adapted by the PI and the research assistant of this study to reflect changes 
to the aim of this research. The interviews were approximately 1 hour, and 
participants were provided $40. The interviews were conducted in-person at an 
agreed-upon community site and time (e.g., coffee shop) and were audio-
recorded. The field guide included semi-structured, open-ended questions on 
identifying perceptions regarding the range of contextual factors that influence 
the opioid epidemic in the community and specific attention to perceptions 
around the scope of the epidemic and how it changed over the past decade; 
health consequences associated with injection opioid use; drug availability (e.g., 
where do the drugs come from and how do people who use get them?); and a 
range of contextual factors, including social and structural factors (e.g., illegal 
sources), that influence OUD and overdose among residents. The interviews also 
focused on identifying formal and informal strategies and interventions. In this 
paper, the focus is on participant perspectives on treatment and harm reduction 
strategies; additional results on community and social factors are reported 




All interview audio recordings were transcribed. Transcripts were read in entirety 
and imported into the qualitative data management software NVivo 1222 for 
analysis using the inductive grounded theory approach.23 Three study team 
members, including the PI, research assistant, and graduate student researcher, 
all of whom have extensive qualitative research experience, met weekly to develop 
the codebook. All segments of text within each interview addressing a priori 
thematic areas were indexed under a common heading. The team began by using 
the components of the interview field guide (e.g., changes in opioid epidemic over 
time) and then expanded with more specific codes identified as a result of the 
review and analysis process, such as themes covering “different opinions 
regarding treatment” and “crime and its relationship to use.” The team double-
coded 30 percent of the interviews to ensure inter-rater reliability and reviewed 
and resolved all coding discrepancies. Upon completion of coding, all team 
members reviewed transcript excerpts from the codebook to identify emergent 
themes related to our research. 
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Conflicting perspectives about opioid dependence lay the foundation for the 
polarizing community perspectives on opioid treatment and general 
disagreement regarding abstinence-based recovery versus harm reduction 
approaches, as well as the role of stigma and police involvement in shaping views 
and access to harm reduction approaches to treatment. 
 
Perceptions of Opioid Dependence 
The concept of opioid dependence was understood differently among participants, 
where some discussed individual choices or personal experiences motivating use 
while others identified structural influences. Some participants, including people 
with a history of opioid use and treatment providers, communicated that the 
problems associated with opioid use and dependence (often referred to in 
communities as “addiction”) were the direct result of an individual’s opioid use 
rather than a cause or driver of use. However, other participants viewed the issue 
from a broader perspective shared their beliefs that opioid use is influenced by 
external community factors and pervasive structural problems. Participants 
referenced economic change and disadvantage, community isolation, lack of 
employment opportunities and social spaces, and the high prevalence of mental 
illness as facilitators for high opioid use within the community: 
 
Because if you know anything about [this area]… you would think it's almost 
like in a war zone. You see all these abandoned houses in the community. You 
see lots with grass growing six feet high. You just see trash in the 
community. It's just a depressing area. And when people live in a depressed 
area, they have a tendency to become depressed themselves. And depression 
leads to something to anesthetize themselves, something like a drug or alcohol 
just to get through a day, you know? (Interview 13, service provider)  
 
Discussions regarding reasons for use, as well as problems resulting from use, 
were divergent in nature and typically placed the onus for addressing opioid use 
either on the person who uses opioids or external factors, but rarely both. 
Similarly, understanding of opioid use fell into two schools of thought: OUD as 
an illness or lifestyle. Beliefs about opioid use as a lifestyle were often moral or 
ethical in nature; beliefs about use as inherently “wrong” meant individuals with 
OUD and/or those who have experienced an overdose were less deserving of the 
quality or quantity of treatment offered for other behavioral health conditions. 
Some participants reported hearing others in the community expressing these 
views: 
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And so, I just think that there's not enough people that really want it to go away 
on both sides… And you got people that are now saying, "Hey, forget Narcan. 
Let him die." Wow…To let a human being – just to say that is crazy to me, 
however this person may die, or not die, or be dying, I don't know. But to say 
that, "Just let him die," that speaks volumes about our country right now or our 
humanity. (Interview 5, community leader) 
 
Perceptions of Opioid Treatment Approaches 
Most participants were split between two schools of thought regarding treatment: 
abstinence-based recovery and harm reduction approaches such as MOUD. It 
was rare for a participant to support the implementation of both treatment 
modes within this community. Many participants also expressed a lack of 
knowledge regarding MOUD and other harm reduction strategies. Some 
participants who were aware of MOUD as a treatment option expressed 
disapproval from reduced focus on sobriety or “getting clean.” 
 
Detox. Participants beliefs on how to address the epidemic in the community 
differed widely. Some participants stated that availability of any treatment in the 
community, including detox, is an important missing piece; other participants 
did not believe detox programs are effective treatment mechanisms for OUD: 
The detox doesn’t seem to be so effective... You feel better about yourself and 
then you go right back to using because really you haven’t been clean long 
enough for your mind and everything to heal. It’s just a long process. You used 
all those years, you’re not just going to get better in 30 days. (Interview 15, 
resident with a history of use) 
 
Medications for opioid use disorder (MOUD). Like opinions on detox, 
participants had strong beliefs about strategies employing harm reduction. Many 
participants understood harm reduction MOUD approaches, Methadone being 
the most recognized, as an extension and continuation of opioid use, or “not 
clean”: 
For me, any type of opiates in your body is still addictive. And so, I’m an old-
fashioned recovery type of guy … You still have the same behavior, the nodding. 
And if you come into a meeting off the medicine when I’m clean, and that’s a 
trigger for me. (Interview 11, resident with a history of use) 
 
Understanding MOUD methods as “still addictive” often led participants to 
describe a tension between harm reduction and abstinence-based recovery. 
Several participants in the study recounted situations in which individuals 
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attempting to participate in Narcotics Anonymous (NA) meetings or live-in 
recovery houses were forced away by peers or leaders: 
The recovery community as a whole has a very shitty attitude towards 
methadone and suboxone. I’ve seen people chased out of the rooms of 12-step 
recovery meetings and recovery because… wanted to do methadone or 
suboxone… they say, ‘Oh, you’re still addicted.’ (Interview 12, resident who 
currently uses) 
 
Naloxone. Like the use of MOUD as a mechanism for addressing the opioid crisis, 
many participants disagreed about use of Naloxone (Narcan)on individuals who 
overdose in the community. Some participants agreed with the practice, and 
some did not: 
I’ve heard both sides of it. It seems that anybody that has had experience with 
opioids themselves obviously is for the use of Narcan. And… people that are 
more so conservative… they might say, “Well, if you shoot this Narcan then this 
junkie is just going to get up and rob my grandmother the next day. (Interview 
12, resident who currently uses) 
 
Further, several participants identified discomfort with using limited community 
resources on Naloxone as an intervention for opioid overdose, particularly when 
individuals need intervention multiple times: 
We have police responding to overdoses almost every day. I think that's taken 
away from a lot of our elderly that might need that same medical attention or – 
I still have a problem with all the Narcan that's being used. If my mother's 
having a heart-attack, and the police are going for the third time the same day 
to save someone who's overdosing. And that's medical attention that somebody 
else is not getting…(Interview 4, resident involved in drug use prevention 
program) 
 
Policing as a Strategy. Like the use of MOUD as a mechanism for addressing 
the opioid crisis, the use of police, arrest, and incarceration, as well as mandated 
treatment as a result of interaction with the criminal justice system, was 
polarizing for participants. Some participants adamantly believed more police 
involvement was necessary to curb opioid use in the community. One participant 
felt individuals arrested for using opioids get off too lightly, which does not “stop” 
use:  
And most of the people that get caught with heroin… get a pat on their hand. 
A pat on the hand… And they doing it again. And it’s like 
they ain’t stopping them. They doing nothing to stop them. (Interview 11, 
resident with a history of use)  
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Other participants, including members of local law enforcement, believed jailing 
individuals for using opioids would not solve the problem. Likewise, many 
participants disagreed about police use of Narcan on individuals who overdose 
in the community. Some participants agreed with the practice, and some did 
not:  
I’ve heard both sides of it. It seems that anybody that has had experience with 
opioids themselves obviously is for the use of Narcan. And… people that are 
more so conservative… they might say, “Well, if you shoot this Narcan then this 
junkie is just going to get up and rob my grandmother the next day. (Interview 
12, resident who currently uses)  
 
There was no clear consensus on police presence as a tool for arrest, treatment, 
or both. Some individuals believed if a police officer responded to an overdose 
and used Naloxone that the individual should be arrested and, perhaps, forced 
into treatment. 
 
Multiple or combined approaches. Participants rarely expressed desire for 
using both harm reduction and abstinence-based recovery programs. The few 
participants who did support a multi-layered approach, either individually or as 
a community practice, felt combining MOUD, NA, and/or recovery homes was 
helpful:  
I’m clean now. I’m on methadone. It helps. A lot of people were against it, but I 
think it helps. It’s better than shooting dope and chasing it every day, and I feel 
like I’m just better on it for now as long as I use it how it’s supposed to. I don’t 
want to be on it the rest of my life. I have a goal, a therapist. I do treatment. I 
go to groups. I do the meetings every night. I have a sponsor. I have a home 




Participants in this study had a wide range of perspectives about why OUD and 
opioid overdose are prevalent in their community, as well as varying opinions 
about the best treatment and overdose prevention methods for residents with 
OUD and/or experiencing an overdose. Viewing OUD as an illness versus a 
lifestyle may cause factions among those interested in working to address the 
crisis. While some participants identified structural- and community-level 
factors impacting use, others believed individual opioid use was the cause, 
rather than a result, of the community’s problems. Residents’ beliefs about 
opioids, the people who use them, and appropriate treatment tap into moral and 
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ethical perspectives. Most participants were split between two schools of thought 
regarding treatment: abstinence-based recovery and harm reduction 
approaches such as MOUD. It was rare for a participant to 
support the implementation of both treatment modes within this community. 
Many participants also expressed a lack of knowledge regarding MOUD and other 
harm reduction strategies. Some participants who were aware of MOUD as a 
treatment option expressed disapproval from reduced focus on sobriety or 
“getting clean.” These views align with notions found in previous literature on 
perceived negative side effects and avoidance of using MOUD, which may be 
influenced by policy and social norms.24–26 
 
Diverse community perspectives, stigma of harm reduction strategies, and lack 
of knowledge of evidence-based interventions may make it difficult for small 
communities with few resources to implement a comprehensive plan to address 
OUD and overdose in their communities. In addition, community leadership may 
face challenges in acquiring funding and support for their constituents’ needs, 
particularly when there is profound disagreement and lack of clear guidance 
regarding effective community-level interventions. These systemic and 
community-level challenges have been previously documented as particular 
barriers in rural and non-urban communities, where resource constraints are 
often greater.25,27,28 Future public health education should provide knowledge of 
evidence-based approaches, as well as advocate for less dichotomy and either/or 
ideologies in the OUD treatment and overdose prevention spheres, particularly 
in economically disadvantaged areas such as the case community in this study. 
Community plans for opioid treatment could incorporate multi-level 
interventions that provide education and access to both harm reduction 
strategies and abstinence-based support, following the example of the 
multimodal treatment approaches introduced and advocated for in the mental 
health literature.29–31 
 
Similarly, the role of police and the criminal legal system is 
another challenging area of disagreement for communities facing an opioid 
crisis. These results reflect previously identified barriers to Naloxone 
acceptance (e.g., cost, legality, and lack of knowledge of distribution) and 
suggest the need to uncover ways to implement policies and increase harm 
reduction strategies while reducing stigma and mistrust.32,33 One promising 
harm reduction intervention is the law enforcement assisted diversion (LEAD) 
program that diverts individuals from the criminal legal system to case 
management programs for a range of support services; LEAD is associated with 
lower odds of arrest and felony charges and is gaining support across the country 
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since its launch in 2011.34 However, disagreement within the community 
regarding the role of police and the effectiveness of criminalization, mandated 
treatment, and the use of Naloxone makes it difficult for effective community 
planning and programming, calling for additional analyses 
around these outcomes.  
 
These qualitative findings are limited to non-urban Appalachian PA. The 20 
stakeholder participants may not represent the full breadth of community 
perspectives and may contain bias as a result of the snowball sampling frame. 
However, these results suggest division in community perspectives may be a 
factor in other geographic areas with limited knowledge, resources, or access to 
care. Future research, even in predominantly white communities like this case 
community, should explore the relationships between race, socioeconomic 
status, and the different community perspectives of opioid crises and treatment.  
 
Our results highlight the importance of expanding treatment options in smaller 
communities. Pilot-testing MOUD interventions in this case community, for 
example, may be an effective next step in understanding how to incorporate 
evidence-based harm reduction approaches in small communities affected by the 
opioid crisis.  
 
SUMMARY BOX  
What is already known about this topic? The Appalachian region has substantially 
higher overdose mortality rates compared to the non-Appalachian United States. Rural 
communities face barriers to opioid treatment including concerns about stigma and lack 
of treatment services, and challenges related to polarizing views of OUD and overdose 
have been prevalent in treatment and recovery spheres for decades, though less 
frequently discussed in the literature. 
What is added by this report? Our findings illustrate how conflicting perspectives 
about opioid use, OUD, and opioid overdose lay the foundation for the polarizing 
community perspectives on opioid treatment and overdose prevention and general 
disagreement regarding the legitimacy of harm reduction approaches versus abstinence-
based recovery plans.  
What are the implications for future research? Future public health education 
should provide knowledge of evidence-based approaches, as well as advocate for less 
dichotomy in the treatment sphere, particularly in economically disadvantaged areas 
such as the case community in this study. Community plans for OUD care and overdose 
prevention could incorporate multi-level interventions that provide education and 
access to harm reduction strategies within the full spectrum of OUD care.   
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